Metabolic effects of tesamorelin in HIV-associated lipodystrophy

Key finding

In 412 HIV patients with abdominal fat accumulation, 2 mg/day tesamorelin for 26 weeks significantly reduced visceral adipose tissue and improved triglycerides vs placebo, without worsening glucose.

Method / model

Phase 3 randomised, double-blind, placebo-controlled trial.

Relevance

Pivotal human RCT for tesamorelin (GHRH analog) visceral-fat reduction.

Falutz, J. et al. (2007). Metabolic effects of tesamorelin in HIV-associated lipodystrophy. NEJM, 357(23), 2359-2370.